title: Anti-inflammatory properties of a new undecyl-rhamnoside (APRC11) against P. acnes.
abstract: Acne vulgaris is a skin disease affecting pilosebaceous glands in which Propionibacterium acnes (P. acnes) induced inflammation plays a central role. In order to develop new therapies against the inflammatory events, we evaluated the modulating effect of a new undecyl-rhamnoside, APRC11, on different markers of the inflammation. For this purpose, normal human keratinocytes taken from five healthy donors were pre-incubated for 24 h with APRC11 or Zinc Gluconate (Zn) which was used as reference molecule for its anti-inflammatory properties. Then, keratinocytes were stimulated with P. acnes Membrane Fraction for 6 h, in the presence of either APRC11 or Zn. Different markers were evaluated at mRNA level using a Luminex-based Quantigene array system and at protein level using an ELISA test and a Luminex array system. Results showed that P. acnes significantly increased the expression of IL-1α, IL-1RA, IL-8 and MMP-9. A 24-h treatment with APRC11 prior to the P. acnes stimulation down-regulated the P. acnes-induced cytokines over expression (IL-1α, IL-8 and MMP-9) and up-regulated IL-1RA level in a similar manner than Zn. These regulations were noted at both protein and mRNA levels. In conclusion, the new undecyl-rhamnoside APRC11 is able to down-regulate the expression of molecules implicated in cutaneous inflammation and whose expression is induced by P. acnes, confirming its potential interest in inflammatory acne.
authors: Nantes Cedex, France.
authors: O
authors: O
authors: Isard
authors: M
authors: M
authors: Lévêque
authors: A C
authors: AC
authors: Knol
authors: M F
authors: MF
authors: Ariès
authors: A
authors: A
authors: Khammari
authors: J M
authors: JM
authors: Nguyen
authors: N
authors: N
authors: Castex-Rizzi
authors: B
authors: B
authors: Dréno
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy / Q000209:etiology / Q000276:immunology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000942:Antigens, Bacterial / Q000276:immunology; D002478:Cells, Cultured; D005786:Gene Expression Regulation / Q000276:immunology; D005942:Gluconates / Q000494:pharmacology; D016908:Gram-Positive Bacterial Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D053582:Interleukin-1alpha / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D016209:Interleukin-8 / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D015603:Keratinocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D011425:Propionibacterium acnes / Q000276:immunology* / Q000472:pathogenicity; D014476:Undecylenic Acids / Q000494:pharmacology*
chemical_list: D000893:Anti-Inflammatory Agents; D000942:Antigens, Bacterial; D005942:Gluconates; D053590:Interleukin 1 Receptor Antagonist Protein; D053582:Interleukin-1alpha; D016209:Interleukin-8; D014476:Undecylenic Acids; D020780:Matrix Metalloproteinase 9; C030691:gluconic acid